The applicability of MIB‐1, a monoclonal antibody directed against the Ki‐67 antigen, was studied in the PC‐82 and LNCaP prostatic tumor models at various levels of proliferative activity. Statistically significant correlations were found in LNCaP cultures between Ki‐67 and MIB‐1 scores (r = 0.84, P < 0.001), and in PC‐82 tumors between MIB‐1 scores and paraffin tissue Ki‐67 (pKi‐67) (r = 0.90, P < 0.001), frozen tissue Ki‐67 (fKi‐67) (r = 0.86, P < 0.001), and BrdU uptake (r = 0.70, P < 0.001), respectively. pKi‐67 scores were double the fKi‐67 scores, which may be due to methodological differences. MIB‐1 scores exceeded both the fKi‐67 and pKi‐67 scores. The affinity of MIB‐1 for the antigen is much higher than the affinity of Ki‐67, which may explain the differences. MIB‐1 is a promising means of evaluating the presence of only minute amounts of the Ki‐67 antigen in paraffin‐embedded human tumor material, especially in relatively slowly growing tumors.

BrdU, immunohistochemistry, LNCaP, PC-82, proliferative activity,
The Prostate
Department of Urology

Noordzij, M.A, van der Kwast, Th.H, van Steenbrugge, G.J, van Weerden, W.M, Oomen, M.H.A, & Schröder, F.H. (1995). Determination of Ki-67 defined growth fraction by monoclonal antibody MIB- I in formalin-fixed, paraffin-embedded prostatic cancer tissues. The Prostate, 27(3), 154–159. doi:10.1002/pros.2990270306